论文部分内容阅读
目的:对吗替麦考酚酯和麦考酚钠用于肾移植后免疫抑制进行药物经济学评价。方法:基于社会视角,采用二次文献研究和模型研究方法,根据接受肾移植后患者健康状态发展规律,构建Markov模型,以成本效果比、成本效用比作为评价指标,并对结果进行敏感度分析。结果:在10个模型周期内,EC-MPS组肾移植患者获得的生命年和质量调整生命年分别为8.4年和6.1年,MMF组为7.5年和5.0年。EC-MPS组肾移植患者每获得一个生命年和质量调整生命年需付出的年医疗费用分别为47 936元和66 011元,MMF组为63 513元和95 270元。结论:EC-MPS用于肾移植后免疫抑制较MMF更具有成本效果。
OBJECTIVE: To evaluate the pharmacokinetics of mycophenolate mofetil and mycophenolate for immunosuppression after renal transplantation. Methods: Based on the social perspective, the second-order literature and model research methods were used to establish the Markov model according to the development of patients’ health status after kidney transplantation. The cost-effectiveness ratio and cost-effectiveness ratio were used as evaluation indexes and the sensitivity of the results was analyzed . Results: The life span and quality-adjusted life span of EC-MPS group were 8.4 years and 6.1 years respectively in 10 model cycles, 7.5 years and 5.0 years in MMF group. The yearly medical expenses for each year of life and quality-adjusted life of EC-MPS patients were 47 936 yuan and 66 011 yuan, respectively. The MMF group was 63 513 yuan and 95 270 yuan respectively. Conclusion: EC-MPS is more cost-effective than MMF in immunosuppression after renal transplantation.